Merck Loses Trademark Suit Against Tianjin Zhongxin Pharmaceutical Group
This article was originally published in PharmAsia News
Executive Summary
Beijing Municipal Higher People's Court has rejected Merck's appeal to the Trademark Appeal Board under the State Administration for Industry and Commerce. It ruled that the registration of Tianjin Zhongxin Pharmaceutical Group's trademark logo should be approved. In 1998, Tianjin Zhongxin applied for its trademark logo registration, which Merck objected, claiming that the image was similar to its registered trademark in China and requested protection of the well-known logo. Insiders point out that the case reflects a major issue: the exhaustive policy of IP rights whereby ownership is secured only after completing all procedures, including trademark registration, administrative review and appeal of administrative proceeding. (Click here for more - Chinese Language)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.